National Institute of Allergy and Infectious Diseases (NIAID): HIV Infections trials

The registry lists 728 HIV Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 9 are open to participants now and 104 have results posted.

Phase 1 327Phase 2 183Phase 3 57Phase 4 7No phase 195(a study in two phases counts in both)

Studies

Page 2 of 8. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug UsersTerminatedNCT00270257Phase 3Results posted
• Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAARTCompletedNCT00270205Phase 1/2Results posted
• Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-InfectionTerminatedNCT00239733Phase 4Results posted
• Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving BirthCompletedNCT00109590Phase 2Results posted
• Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at BirthCompletedNCT00102960Phase 3Results posted
• Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During PregnancyCompletedNCT00099632Phase 2Results posted
• Preventing Sexual Transmission of HIV With Anti-HIV DrugsCompletedNCT00074581Phase 3Results posted
• Using Nevirapine to Prevent Mother-to-Child HIV Transmission During BreastfeedingCompletedNCT00074412Phase 3Results posted
• Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral TxCompletedNCT00071890Phase 2Results posted
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After PregnancyCompletedNCT00042289Results posted
• Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected ChildrenCompletedNCT00039741Phase 2/3Results posted
• Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV DrugsCompletedNCT00016718Phase 1/2Results posted
• Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and AdolescentsCompletedNCT00006604Phase 1/2Results posted
• Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT06585891Phase 1
• A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIVActive, not recruitingNCT06557785Phase 1
• The Tatelo Plus StudyActive, not recruitingNCT06508749Phase 1/2
• Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVCompletedNCT05551273Phase 2
• Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATIWithdrawnNCT05079451Phase 1
• Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionActive, not recruitingNCT04340596Phase 1
• Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult ParticipantsWithdrawnNCT04041674Phase 1
• Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected AdultsWithdrawnNCT03505060Phase 1
• Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative AdultsCompletedNCT03393468Phase 1
• Safety and Immune Response to a Clade C DNA HIV VaccineCompletedNCT02997969Phase 1
• Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected AdultsCompletedNCT02654080Phase 1
• CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)CompletedNCT02652546Phase 1
• Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima PeruCompletedNCT02630082Not applicable
• Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT02599896Phase 1
• Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected AdultsCompletedNCT02431767Phase 1
• Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048CompletedNCT02419456Phase 1
• Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048CompletedNCT02356302Phase 1
• Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected AdultsCompletedNCT02296541Phase 1
• Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected AdultsCompletedNCT02207920Phase 1
• Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected AdultsCompletedNCT02165267Phase 1
• Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral TherapyCompletedNCT02028403Phase 1
• Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT01993706Phase 1
• Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of AgeWithdrawnNCT01975012Phase 1/2
• Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected AdultsWithdrawnNCT01970449Phase 1
• Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected AdultsWithdrawnNCT01964937Phase 1
• Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South AfricaWithdrawnNCT01927835Phase 1
• Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV MedicationsWithdrawnNCT01909414Phase 1
• Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected AdultsCompletedNCT01783977Phase 1
• Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected AdultsCompletedNCT01578889Phase 1
• Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in UgandaCompletedNCT01549509Phase 1
• Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in UgandaCompletedNCT01549470Phase 1
• Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant WomenWithdrawnNCT01490671Phase 2
• Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected AdultsCompletedNCT01479296Phase 1
• Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected AdultsCompletedNCT01438606Phase 1
• Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)CompletedNCT01423825Phase 1
• Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical TrialsCompletedNCT01376726Phase 1
• Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected AdultsCompletedNCT01266616Phase 1
• Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected AdultsCompletedNCT01260727Phase 1
• Antigenic Competition in HIV Preventive VaccinesCompletedNCT01159990Phase 1
• Tenofovir Gel in Pregnancy and LactationCompletedNCT01136759Phase 1
• Extended Follow-Up of Participants in Preventive HIV Vaccine Studies in UgandaCompletedNCT01109342
• Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected AdultsCompletedNCT01103687Phase 1
• Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected AdultsCompletedNCT01095224Phase 1
• Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and BreastfeedingCompletedNCT01066858
• Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult TwinsCompletedNCT01054872Phase 1
• Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection StatusCompletedNCT01040091Phase 1
• Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected AdultsCompletedNCT00991354Phase 1
• Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected IndividualsCompletedNCT00955006Phase 1
• Early Immune Responses to Vaccination - A Substudy to HVTN 205CompletedNCT00908323
• Intensive Viral Dynamics Substudy of A5248CompletedNCT00852618
• Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive AdultsCompletedNCT00820846Phase 2
• Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 VectorCompletedNCT00801697Phase 1
• Hepatitis B and HIV Co-Infection in Patients in UgandaCompletedNCT00782158
• Bone Mineral Density Substudy - An Ancillary Study to MTN-003CompletedNCT00729573
• Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector InjectionCompletedNCT00709605Phase 1
• Response to Standard HIV Treatment in Bamako, MaliCompletedNCT00703404
• Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy AdultsCompletedNCT00695877Phase 1
• Study of Provider Computer Alerts Designed to Improve Delivery of HIV CareCompletedNCT00678600Not applicable
• Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in ThailandCompletedNCT00672412Phase 1/2
• Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)CompletedNCT00660972Phase 1
• Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in UgandaCompletedNCT00639938Phase 3
• Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy AdultsCompletedNCT00618605Phase 1
• HIV Resistance and Treatment StrategiesCompletedNCT00581802
• Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative AdultsCompletedNCT00574600Phase 1
• Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean DeliveryCompletedNCT00540605Phase 1
• Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy AdultsCompletedNCT00528489Phase 1
• Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and AfricaWithdrawnNCT00498056Phase 2
• An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected IndividualsCompletedNCT00489385Phase 1
• Phase 1 Safety Study of Two Experimental HIV VaccinesCompletedNCT00479999Phase 1
• A Cluster-Randomized Intervention Trial to Improve Quality of Life for HIV-Infected Individuals in Anhui, ChinaCompletedNCT00479141Not applicable
• Phase I Study of Safety and Persistence of UC-781 Vaginal MicrobicideCompletedNCT00441909Phase 1
• Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load MonitoringCompletedNCT00434070
• Effects of Anti-HIV Therapy on Nervous System FunctionCompletedNCT00432003
• Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy AdultsCompletedNCT00428337Phase 1
• Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African AdultsWithdrawnNCT00415649Phase 2
• Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African AdultsCompletedNCT00413725Phase 2
• Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study ParticipantsCompletedNCT00386035
• Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study ParticipantsCompletedNCT00385632
• Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected AdultsCompletedNCT00384787Phase 1
• Collection of Blood Samples From SMART Study Participants for Future Genetic StudiesCompletedNCT00377169
• Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, ChinaCompletedNCT00346762
• Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected AdultsStatus unknownNCT00331448
• Phase I Study of Vaccination Schedule of Experimental HIV VaccinesCompletedNCT00321061Phase 1
• Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai ChildrenCompletedNCT00312091Phase 1/2
• Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 StudiesCompletedNCT00311688
• Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy AdultsCompletedNCT00301184Phase 1
• Acute HIV Infection Observational StudyCompletedNCT00296660